Form 8-K - Current report:
SEC Accession No. 0001193125-25-165170
Filing Date
2025-07-25
Accepted
2025-07-25 12:23:39
Documents
16
Period of Report
2025-07-25
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d62567d8k.htm   iXBRL 8-K 29327
2 EX-99.1 d62567dex991.htm EX-99.1 19451
7 GRAPHIC g62567dsp1.jpg GRAPHIC 5096
8 GRAPHIC g62567dsp1a.jpg GRAPHIC 5234
  Complete submission text file 0001193125-25-165170.txt   224483

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ima-20250725.xsd EX-101.SCH 3230
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ima-20250725_def.xml EX-101.DEF 14193
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ima-20250725_lab.xml EX-101.LAB 23423
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ima-20250725_pre.xml EX-101.PRE 15068
19 EXTRACTED XBRL INSTANCE DOCUMENT d62567d8k_htm.xml XML 5522
Mailing Address 50 NORTHERN AVE. BOSTON MA 02210
Business Address 50 NORTHERN AVE. BOSTON MA 02210 857-343-8292
Ikena Oncology, Inc. (Filer) CIK: 0001835579 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40287 | Film No.: 251150444
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)